Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
MicroRNAs and triple negative breast cancer.

International journal of molecular sciences

D'Ippolito E, Iorio MV.
PMID: 24284394
Int J Mol Sci. 2013 Nov 11;14(11):22202-20. doi: 10.3390/ijms141122202.

Triple Negative Breast Cancer (TNBC) is a very aggressive tumor subtype, which still lacks specific markers for an effective targeted therapy. Despite the common feature of negativity for the three most relevant receptors (ER, PgR and HER2), TNBC is...

Cite
D'Ippolito E, Iorio MV. MicroRNAs and triple negative breast cancer. Int J Mol Sci. 2013;14(11):22202-20doi: 10.3390/ijms141122202.
D'Ippolito, E., & Iorio, M. V. (2013). MicroRNAs and triple negative breast cancer. International journal of molecular sciences, 14(11), 22202-20. https://doi.org/10.3390/ijms141122202
D'Ippolito, Elvira, and Iorio, Marilena V. "MicroRNAs and triple negative breast cancer." International journal of molecular sciences vol. 14,11 (2013): 22202-20. doi: https://doi.org/10.3390/ijms141122202
D'Ippolito E, Iorio MV. MicroRNAs and triple negative breast cancer. Int J Mol Sci. 2013 Nov 11;14(11):22202-20. doi: 10.3390/ijms141122202. PMID: 24284394; PMCID: PMC3856060.
Copy Download .nbib Format: NLM
Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging.

EBioMedicine

Roy S, Whitehead TD, Quirk JD, Salter A, Ademuyiwa FO, Li S, An H, Shoghi KI.
PMID: 32891051
EBioMedicine. 2020 Sep;59:102963. doi: 10.1016/j.ebiom.2020.102963. Epub 2020 Sep 02.

BACKGROUND: Radiomics analyses has been proposed to interrogate the biology of tumour as well as to predict/assess response to therapy in vivo. The objective of this work was to assess the sensitivity of radiomics features to noise, resolution, and...

Cite
Roy S, Whitehead TD, Quirk JD, et al. Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging. EBioMedicine. 2020;59:102963doi: 10.1016/j.ebiom.2020.102963.
Roy, S., Whitehead, T. D., Quirk, J. D., Salter, A., Ademuyiwa, F. O., Li, S., An, H., & Shoghi, K. I. (2020). Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging. EBioMedicine, 59102963. https://doi.org/10.1016/j.ebiom.2020.102963
Roy, Sudipta, et al. "Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging." EBioMedicine vol. 59 (2020): 102963. doi: https://doi.org/10.1016/j.ebiom.2020.102963
Roy S, Whitehead TD, Quirk JD, Salter A, Ademuyiwa FO, Li S, An H, Shoghi KI. Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging. EBioMedicine. 2020 Sep;59:102963. doi: 10.1016/j.ebiom.2020.102963. Epub 2020 Sep 02. PMID: 32891051; PMCID: PMC7479492.
Copy Download .nbib Format: NLM
Basal-like and triple-negative breast cancers: searching for positives among many negatives.

Surgical oncology clinics of North America

Alluri P, Newman LA.
PMID: 24882351
Surg Oncol Clin N Am. 2014 Jul;23(3):567-77. doi: 10.1016/j.soc.2014.03.003.

Triple-negative breast cancers (TNBC) are defined by their failure to express the estrogen receptor, progesterone receptor, and HER2/neu protein markers. This basic feature is clinically relevant because it indicates that these cancers cannot be managed with endocrine or anti-HER2...

Cite
Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am. 2014;23(3):567-77doi: 10.1016/j.soc.2014.03.003.
Alluri, P., & Newman, L. A. (2014). Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surgical oncology clinics of North America, 23(3), 567-77. https://doi.org/10.1016/j.soc.2014.03.003
Alluri, Prasanna, and Newman, Lisa A. "Basal-like and triple-negative breast cancers: searching for positives among many negatives." Surgical oncology clinics of North America vol. 23,3 (2014): 567-77. doi: https://doi.org/10.1016/j.soc.2014.03.003
Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am. 2014 Jul;23(3):567-77. doi: 10.1016/j.soc.2014.03.003. PMID: 24882351; PMCID: PMC4304394.
Copy Download .nbib Format: NLM
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?.

Oncotarget

Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT.
PMID: 25973541
Oncotarget. 2015 May 30;6(15):12890-908. doi: 10.18632/oncotarget.3849.

Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC). We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development. With the ultimate aim...

Cite
Le Du F, Eckhardt BL, Lim B, et al. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget. 2015;6(15):12890-908doi: 10.18632/oncotarget.3849.
Le Du, F., Eckhardt, B. L., Lim, B., Litton, J. K., Moulder, S., Meric-Bernstam, F., Gonzalez-Angulo, A. M., & Ueno, N. T. (2015). Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget, 6(15), 12890-908. https://doi.org/10.18632/oncotarget.3849
Le Du, Fanny, et al. "Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?." Oncotarget vol. 6,15 (2015): 12890-908. doi: https://doi.org/10.18632/oncotarget.3849
Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget. 2015 May 30;6(15):12890-908. doi: 10.18632/oncotarget.3849. PMID: 25973541; PMCID: PMC4536987.
Copy Download .nbib Format: NLM
Dr Sandi Dunn illuminates emerging key treatment approaches and companion diagnostics for triple negative breast cancer.

Expert opinion on investigational drugs

Dunn S.
PMID: 33070643
Expert Opin Investig Drugs. 2020 Dec;29(12):1309-1312. doi: 10.1080/13543784.2020.1839847. Epub 2020 Oct 31.

No abstract available.

Cite
Dunn S. Dr Sandi Dunn illuminates emerging key treatment approaches and companion diagnostics for triple negative breast cancer. Expert Opin Investig Drugs. 2020;29(12):1309-1312doi: 10.1080/13543784.2020.1839847.
Dunn, S. (2020). Dr Sandi Dunn illuminates emerging key treatment approaches and companion diagnostics for triple negative breast cancer. Expert opinion on investigational drugs, 29(12), 1309-1312. https://doi.org/10.1080/13543784.2020.1839847
Dunn, Sandra. "Dr Sandi Dunn illuminates emerging key treatment approaches and companion diagnostics for triple negative breast cancer." Expert opinion on investigational drugs vol. 29,12 (2020): 1309-1312. doi: https://doi.org/10.1080/13543784.2020.1839847
Dunn S. Dr Sandi Dunn illuminates emerging key treatment approaches and companion diagnostics for triple negative breast cancer. Expert Opin Investig Drugs. 2020 Dec;29(12):1309-1312. doi: 10.1080/13543784.2020.1839847. Epub 2020 Oct 31. PMID: 33070643.
Copy Download .nbib Format: NLM
Subtyping of triple-negative breast cancer.

Clinical advances in hematology & oncology : H&O

Mayer IA.
PMID: 24896546
Clin Adv Hematol Oncol. 2013 Nov;11(11):731-2.

No abstract available.

Cite
Mayer IA. Subtyping of triple-negative breast cancer. Clin Adv Hematol Oncol. 2013;11(11):731-2
Mayer, I. A. (2013). Subtyping of triple-negative breast cancer. Clinical advances in hematology & oncology : H&O, 11(11), 731-2.
Mayer, Ingrid A. "Subtyping of triple-negative breast cancer." Clinical advances in hematology & oncology : H&O vol. 11,11 (2013): 731-2.
Mayer IA. Subtyping of triple-negative breast cancer. Clin Adv Hematol Oncol. 2013 Nov;11(11):731-2. PMID: 24896546.
Copy Download .nbib Format: NLM
Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.

Asia-Pacific journal of clinical oncology

Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S.
PMID: 28815913
Asia Pac J Clin Oncol. 2018 Feb;14(1):32-39. doi: 10.1111/ajco.12748. Epub 2017 Aug 16.

Triple negative breast cancer (TNBC) is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. It also has a distinct epidemiology. TNBCs are frequently of high histologic grade, typically more aggressive...

Cite
Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol. 2017;14(1):32-39doi: 10.1111/ajco.12748.
Khosravi-Shahi, P., Cabezón-Gutiérrez, L., & Custodio-Cabello, S. (2018). Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia-Pacific journal of clinical oncology, 14(1), 32-39. https://doi.org/10.1111/ajco.12748
Khosravi-Shahi, Parham, et al. "Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies." Asia-Pacific journal of clinical oncology vol. 14,1 (2018): 32-39. doi: https://doi.org/10.1111/ajco.12748
Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol. 2018 Feb;14(1):32-39. doi: 10.1111/ajco.12748. Epub 2017 Aug 16. PMID: 28815913.
Copy Download .nbib Format: NLM
Ensemble outlier detection and gene selection in triple-negative breast cancer data.

BMC bioinformatics

Lopes MB, Veríssimo A, Carrasquinha E, Casimiro S, Beerenwinkel N, Vinga S.
PMID: 29728051
BMC Bioinformatics. 2018 May 04;19(1):168. doi: 10.1186/s12859-018-2149-7.

BACKGROUND: Learning accurate models from 'omics data is bringing many challenges due to their inherent high-dimensionality, e.g. the number of gene expression variables, and comparatively lower sample sizes, which leads to ill-posed inverse problems. Furthermore, the presence of outliers,...

Cite
Lopes MB, Veríssimo A, Carrasquinha E, et al. Ensemble outlier detection and gene selection in triple-negative breast cancer data. BMC Bioinformatics. 2018;19(1):168doi: 10.1186/s12859-018-2149-7.
Lopes, M. B., Veríssimo, A., Carrasquinha, E., Casimiro, S., Beerenwinkel, N., & Vinga, S. (2018). Ensemble outlier detection and gene selection in triple-negative breast cancer data. BMC bioinformatics, 19(1), 168. https://doi.org/10.1186/s12859-018-2149-7
Lopes, Marta B, et al. "Ensemble outlier detection and gene selection in triple-negative breast cancer data." BMC bioinformatics vol. 19,1 (2018): 168. doi: https://doi.org/10.1186/s12859-018-2149-7
Lopes MB, Veríssimo A, Carrasquinha E, Casimiro S, Beerenwinkel N, Vinga S. Ensemble outlier detection and gene selection in triple-negative breast cancer data. BMC Bioinformatics. 2018 May 04;19(1):168. doi: 10.1186/s12859-018-2149-7. PMID: 29728051; PMCID: PMC5936001.
Copy Download .nbib Format: NLM
MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer.

Artificial cells, nanomedicine, and biotechnology

Tang Q, Ouyang H, He D, Yu C, Tang G.
PMID: 31284781
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2800-2809. doi: 10.1080/21691401.2019.1638791.

Triple-negative breast cancer (TNBC) is a distinct subtype of breast cancer characterized by high recurrence rates and poor prognosis compared to other breast cancers. MicroRNAs (miRNAs) are small non-coding RNAs that regulate the expression of various post-transcriptional gene and...

Cite
Tang Q, Ouyang H, He D, et al. MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):2800-2809doi: 10.1080/21691401.2019.1638791.
Tang, Q., Ouyang, H., He, D., Yu, C., & Tang, G. (2019). MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer. Artificial cells, nanomedicine, and biotechnology, 47(1), 2800-2809. https://doi.org/10.1080/21691401.2019.1638791
Tang, Qian, et al. "MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer." Artificial cells, nanomedicine, and biotechnology vol. 47,1 (2019): 2800-2809. doi: https://doi.org/10.1080/21691401.2019.1638791
Tang Q, Ouyang H, He D, Yu C, Tang G. MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2800-2809. doi: 10.1080/21691401.2019.1638791. PMID: 31284781.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries